KPTI logo

KPTI
Karyopharm Therapeutics Inc

7,906
Mkt Cap
$200.64M
Volume
997,988.00
52W High
$10.99
52W Low
$3.65
PE Ratio
-0.54
KPTI Fundamentals
Price
$7.67
Prev Close
$8.90
Open
$8.80
50D MA
$7.97
Beta
1.01
Avg. Volume
501,371.51
EPS (Annual)
-$17.93
P/B
-0.76
Rev/Employee
$640,644.74
$250.34
Loading...
Loading...
News
all
press releases
Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News·1d ago
News Placeholder
More News
News Placeholder
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3...
PR Newswire·1d ago
News Placeholder
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm to Participate at Upcoming Investor Conferences Karyopharm to Participate at Upcoming Investor Conferences PR Newswire NEWTON, Mass., May 12, 2026 NEWTON, Mass., May 12, 2026 /PRNewswire...
PR Newswire·3d ago
News Placeholder
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 PR Newswire NEWTON, Mass., May 7, 2026...
PR Newswire·8d ago
News Placeholder
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $13.00 at HC Wainwright
HC Wainwright lifted their target price on Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday...
MarketBeat·9d ago
News Placeholder
Karyopharm Therapeutics (KPTI) Projected to Post Quarterly Earnings on Monday
Karyopharm Therapeutics (NASDAQ:KPTI) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat.com...
MarketBeat·18d ago
News Placeholder
Piper Sandler Reiterates Overweight Rating for Karyopharm Therapeutics (NASDAQ:KPTI)
Piper Sandler reaffirmed an "overweight" rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday...
MarketBeat·18d ago
<
1
2
...
>

Latest KPTI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.